News
-
-
-
PRESS RELEASE
Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
AL-S Pharma AG presents additional Phase 2 data of lead program AP-101 at AD/PD International Conference showing disease modification in ALS patients. AP-101 targets misfolded SOD1 to inhibit disease progression